Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?

Renguo Guan,Jie Mei,Wenping Lin,Min Deng,Shaohua Li,Rongping Guo
DOI: https://doi.org/10.1007/s12072-023-10535-8
IF: 9.029
2023-05-03
Hepatology International
Abstract:The level of C‐reactive protein (CRP) and alpha‐fetoprotein (AFP) in immunotherapy (CRAFITY) score was associated with the prognosis of hepatocellular carcinoma (HCC) patients treated with immunotherapy. Based on the CRAFITY score, this study aimed to investigate the efficacy and safety of locoregional-immunotherapy for treating HCC patients.
gastroenterology & hepatology
What problem does this paper attempt to address?